Vestibular Rehabilitation With Intratympanic Drug Therapy in Meniere's Disease
Objective Vestibular Evaluation & Rehabilitation With Intratympanic Dexamethasone and Gentamicin in Meniere's Disease
1 other identifier
interventional
93
1 country
1
Brief Summary
Intractable symptoms of Meniere's disease will be treated with intratympanic steroids. At the same time intratympanic dexamethasone will be used to rescue hearing
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 22, 2022
CompletedFirst Submitted
Initial submission to the registry
April 24, 2022
CompletedFirst Posted
Study publicly available on registry
May 2, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2022
CompletedMay 2, 2022
April 1, 2022
1.1 years
April 24, 2022
April 27, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Vestibular Rehabilitation
Improvement in vestibular severity index
Three months
Study Arms (1)
Vestibular severity index improvement
EXPERIMENTALImprovement in vestibular symptoms with intratympanic gentamicin
Interventions
Intratympanic gentamicin and dexamethasone administered in two doses one week apart
Intratympanic gentamicin and dexamethasone administered in two doses one week apart
Eligibility Criteria
You may qualify if:
- All patients of unilateral Meniere's disease with severe vestibular symptoms
You may not qualify if:
- Bilateral disease, operated cases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CMH Quetta
Quetta, Balochistan, 87300, Pakistan
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zeeshan Ayub, FCPS
CMH Quetta
- STUDY CHAIR
Zeeshan Ayub, FCPS
CMH Quetta
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Masking Details
- For Alleviation of Intractable symptoms of Meniere's disease will be treated with intratympanic steroids. Measured with pre and post therapy vestibular severity index. At the same time intratympanic dexamethasone will be used to rescue hearing measured with speech reception threshold and speech discrimination threshold
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor ENT
Study Record Dates
First Submitted
April 24, 2022
First Posted
May 2, 2022
Study Start
April 1, 2021
Primary Completion
April 22, 2022
Study Completion
May 30, 2022
Last Updated
May 2, 2022
Record last verified: 2022-04